

Discover the Global Rare Disease Treatment Market Forecast to 2022-2030: Know the Trends Along with SWOT Analysis

Global Rare Disease Treatment Market is Expanding at a CAGR of 15.76% over the Forecast Period (2022 – 2030)

PUNE, MAHARASHTRA, INDIA, April 7, 2022 /EINPresswire.com/ -- Rare diseases, often known as orphan diseases, are a range of disorders that affect a small fraction of the population and usually show in childhood, but they can also grow in adults via a chronic phase. A rare disease is defined in the United States as a disorder that affects fewer than 200,000 persons in the country.



Congress established this definition in the Orphan Drug Act of 1983. Rare diseases became known as orphan diseases since drug companies were unwilling to accept them in order to create treatments. The Orphan Drug Law made financial incentives to encourage pharmaceutical companies to explore new treatments for rare diseases. In the United States, about 7,000 rare diseases affected more than 30 million individuals. Many rare diseases are deadly, and the majority of them have no treatment. Hundreds of medications for rare diseases have been approved by the FDA, yet the majority of rare diseases do not have FDA-approved treatments. To support the development of rare disease products, the FDA collaborated with numerous individuals and organizations, including patients, caregivers, and drug and device manufacturers. The growing prevalence of rare diseases, aging population, and initiatives by market players are the key factors driving the <u>rare disease treatment market</u> growth over the forecast period.

Rising government assistance, raising awareness among people and social groups, and an increase in research incentives due to the prevalence of non-profit organizations that promote health to cure rare diseases are factors contributing to the rare disease treatment market's growth over the forecast period.

Get PDF sample report with related graphs & charts (Pre & post COVID-19 impact analysis):

https://www.absolutemarketsinsights.com/request_sample.php?id=1127

COVID-19, caused by a coronavirus strain known as severe acute respiratory syndrome coronavirus 2, has spread over the world, threatening the health of billions of people. The COVID-19 pandemic has presented new challenges to all populations throughout the world. According to the World Health Organization (WHO), rare or orphan disease affects less than 5 persons out of every 10,000. It is estimated that there are 5000–8000 (rare diseases) RDs impacting 400 million individuals worldwide, or around one in every 15 people (6.67 percent). During the epidemic, patient organizations were forced to broaden their scope of services, which included everything from providing personal protective equipment and arranging medication to providing psycho-social/mental health care. As a result of these factors, the worldwide rare disease treatment market is growing to cover the patient pool of rare chronic diseases.

Speak to our analyst in case of queries before buying this report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1127

Global Rare Disease Treatment Market Report Highlights

- •In terms of therapeutic indication, the genetic disorder segment registered a sizable market share in 2021. There are numerous causes of rare diseases. The vast majority are assumed to be genetic in nature, resulting from alterations in genes or chromosomes. In some circumstances, disease-causing genetic alterations are passed down through generations. In other circumstances, they appear random in a person who is the first in their family to be diagnosed.
- •By route of administration, the oral segment held a significant share in the rare disease treatment market in 2021 owing to the growing development of oral-based medication from the major players for rare diseases. For instance, In February 2022, Oakrum Pharma, LLC, in collaboration with ANI Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for a generic form of Cystadane1 (betaine anhydrous for oral solution) Powder and given Competitive Generic Therapy (CGT) exclusivity for 180 days. Cystadane is a registered brand of Recordati Rare Diseases Inc.
- •Hospitals and clinics captured the largest revenue by end-user in 2021, as hospitals are the primary point of care for treatment. Furthermore, hospitals provide greater care to their patients, and treatment costs are often reimbursed, which drives adoption.
- •Asia Pacific is anticipated to be the fastest-growing region in the rare disease treatment market over the forecast period. Some of the major developing economies such as China, and India contributing to the growth of the Asia Pacific region owing to the increasing aging population and rapidly increasing cases of rare diseases. The field of rare diseases is complex, heterogeneous, and constantly evolving, with a lack of medical and scientific knowledge. In India, approximately 450 rare diseases have been documented. Furthermore, the government and healthcare institutions are heavily investing in healthcare infrastructure in order to have access to high-tech techniques for rare diseases.

View our exclusive press releases on Industry Global News24

Competitors:

List of Key Players of Global Rare Disease Treatment Market are Mentioned Below:

- •AbbVie Inc.
- Alexion Pharmaceuticals Inc
- •Amgen Inc.
- AOP Orphan Pharmaceuticals GmbH
- AstraZeneca
- Bayer AG
- •□ELGENE CORPORATION
- IISL
- •Bisai Co., Ltd.
- •Janssen Research & Development, LLC
- •Novartis AG
- •Novo Nordisk A/S
- •Bfizer Inc.
- •Rare Disease Therapeutics, Inc.
- •RECORDATI S.p.A.
- •Banofi
- Shire
- Dther Market Participants

Global Rare Disease Treatment Market Segmentation

By Application

oAdults

o@hildren

- •By Route of Administration
- oDral
- olinjectable
- By Indication
- o⊞ematology
- oDncology
- oMusculoskeletal
- oGenetic Disorder
- oEnvenomation
- olardiology & Pulmonology
- o**Endocrinology**
- oMetabolic Disorders
- oNeurologic diseases
- oInfectious Diseases
- olimmunodeficiency
- oInherited disorder

olushing's disease and Cushing syndrome oothers

•By End-User o⊞ospitals and Clinics oSpecialty centers oOthers

By Region

oNorth America (U.S., Canada, Mexico, Rest of North America)

oBurope (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe oAsia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific oMiddle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)

o□atin America (Brazil, Argentina, Rest of Latin America)

Purchase the latest in-depth Rare Disease Treatment Market Report @ https://www.absolutemarketsinsights.com/checkout?id=1127

Top Reports:

Global mRNA Vaccines Market – https://www.absolutemarketsinsights.com/reports/Global-mRNA-Vaccines-Market-2021-2029-1050

Global Non-contact Infrared Thermometer Market –

https://www.absolutemarketsinsights.com/reports/Non-contact-Infrared-Thermometer-2020---2028-789

Our 402+ pages research study on Global Rare Disease Treatment Market will include extensive information on the following pointers:

- •Global Market size and forecast values (2015 2030), in terms of revenue (US\$ Million) by segments/sub-segments; wherein 2015 to 2020 has been considered as historic years, 2021 as the base year, while 2022 to 2030 will be taken as the forecast period.
- •Bplit of the market revenue (US\$ Million) into all the relevant segments & sub-segments across all major regions/countries.
- •Market determinants and influencing factors for all major markets.
- Market Dynamics
- oDrivers
- oRestraints
- oDpportunities
- o@hallenges
- Business & Technological Trends

- •□ovid-19 impact analysis
- •Macro-Economic and Micro-Economic Indicators
- Borter's Five Forces Analysis
- oBargaining Power of Buyers
- oBargaining Power of Suppliers
- ollhreat of New Entrants
- ollhreat of Substitutes
- ollompetitor's Rivalry
- •Market Determinants Radar Chart
- Competitive Benchmarking: Global Presence and Growth Strategies
- oMergers and Acquisitions
- oBroduct Launches
- olinvestments Trends
- oR&D Initiatives
- Market share analysis, taking base year as 2021
- •Detailed profiles of major market participants operating in the market, encompassing information on the following pointers:
- ollompany Details
- ollompany Overview
- oProduct Offerings
- olley Developments
- oEinancial Analysis
- oßWOT Analysis
- oBusiness Strategies
- Key Findings
- •Region-specific reports including North America, Europe, Asia Pacific, Middle East & Africa, and Latin America are also available in our repository.
- The reports can be provided in different languages including French, Korean, Japanese, Arabic, Spanish, German, Russian, Chinese, and other languages.

About Us:

<u>Absolute Markets Insights</u> assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Contact Name: Shreyas Tanna

Company: Absolute Markets Insights

Email Id: sales@absolutemarketsinsights.com

Phone: IN +91-7400-24-24-24, US +1-510-420-1213

Website: www.absolutemarketsinsights.com

Shreyas Tanna Absolute Markets Insights

+1 510-420-1213

email us here

Visit us on social media:

Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/567757312

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.